Biotech Stemline Therapeutics prices upsized IPO at $10, the low end of the range

Comment

Shutterstock photo

Stemline Therapeutics, a biotech developing treatments that target cancer stem cells and tumor bulk, raised $33 million by offering 3.3 million shares (1.0 million more than expected) at $10, the low end of the range of $10 to $12. Stemline Therapeutics plans to list on the NASDAQ under the symbol STML. Aegis Capital Corp. was the sole bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com